ASX Runners of the Week: Argent, Peregrine, NewPeak Metals & Caspin
The article says volatility returned after Trump declared an Iran ceasefire dead, following Iranian strikes on vessels in the Strait of Hormuz and subsequent US air strikes. It notes Brent crude rose above $80/bbl and junior resources stocks rallied. It highlights ASX-listed Argent BioPharma (RGT) up 206% on a US$5.5m CannEpil licensing deal with Splash, and Peregrine Gold (PGD) up 109% and NewPeak Minerals (NPM) up 107% on early gold discoveries.
How this was made
The 30-second read
Why it matters
The newest facts are three company-specific catalysts: (1) Argent’s CannEpil licensing deal with defined economics and milestones, (2) Peregrine’s near-surface gold-bearing paleo gravel discovery and lease application, and (3) NewPeak’s first-hole polymetallic intercept with stated lengths and grades.
Market read
Traders can treat this as a catalyst-driven momentum watch: deal economics for RGT, discovery and permitting pathway for PGD, and first-hole drill results for NPM.
What to watch
For RGT, execution risk remains on Splash initiating and completing trials on schedule. For PGD and NPM, the article notes pending assays and early-stage testing, so grade continuity and economic viability are not yet proven.
Background
The piece frames a week of renewed Middle East shipping and oil volatility, then highlights unusually strong ASX “Runners” largely driven by junior resource and biotech-specific catalysts.
Ticker impact
Argent BioPharma surged after licensing CannEpil globally with Splash, including US$5.5m upfront via convertible-note forgiveness and a 15% royalty.
Near-term upside bias with continued volatility tied to trial timelines and early commercialization expectations.
The article provides specific deal economics (US$5.5m, note forgiveness, 15% royalty) and clear clinical milestones, which are actionable for sentiment and positioning.
Market effects
Renewed interest in junior resources and Aussie biotech, while geopolitical shipping risk keeps energy/defence bid and can amplify cross-asset volatility.
ASX small caps show momentum on deal and early drill/discovery headlines, even as global risk sentiment wobbles.
Strait of Hormuz disruption risk supports commodity sensitivity (oil, and potentially metals via macro risk appetite), but the stock moves here are company-specific.
Counterpoint
Large percentage moves in juniors can reverse quickly if follow-up assays, trial timelines, or permitting outcomes disappoint relative to the initial headline catalyst.
Key entities
- companyArgent BioPharma Ltd
ASX-listed biotech that agreed global licensing for CannEpil with Splash, including upfront consideration via convertible-note forgiveness and a 15% royalty.
- companyPeregrine Gold Ltd
ASX-listed gold explorer that reported extensive gold-bearing paleo gravels at its Newman project and filed a mining lease application.
- companyNewPeak Minerals Ltd
ASX-listed explorer that reported first drill-hole results at Las Opeñas, intersecting a large gold-zinc-silver system with specific intercepts and grades.
- companySplash Beverage Group
NYSE-listed counterparty that gains exclusive global commercialisation rights for CannEpil and assumes development/regulatory burden under the deal.
